Abstract
AIMS: Casdatifan is an orally bioavailable small-molecule hypoxia-inducible factor-2α (HIF-2α) inhibitor currently in development for treating patients with clear cell renal cell carcinomas. The aim of this study was to characterize the pharmacokinetics (PK), pharmacodynamics and safety of casdatifan in healthy participants. METHODS: This first-in-human study (NCT05117554) investigating casdatifan in 70 healthy participants consisted of 3 parts: a double-blind, randomized, placebo-controlled single ascending dose (3-100 mg) part; a multiple ascending dose (15-50 mg once daily) part; and an open-label, fixed sequence, 2-period, drug-drug interaction part to evaluate the effect of multiple doses of casdatifan on the single-dose PK of midazolam. RESULTS: In healthy participants, casdatifan plasma exposure increased dose proportionally over a single dose of 3-100 mg and multiple daily doses of 15-50 mg. The mean half-life of casdatifan was approximately 24 h, and PK parameters did not change over time. Dose- and concentration-dependent reduction, ranging from 41 to 85%, in erythropoietin (a pharmacodynamic biomarker for peripheral, nontumour, HIF-2α inhibition) was observed after single and multiple doses, consistent with HIF-2α pathway inhibition. Results from the midazolam drug-drug interaction part indicated that casdatifan was a weak CYP3A4 inducer at the tested dose. Urine PK data showed that approximately 30% of the overall casdatifan clearance appears to be via renal clearance. CONCLUSIONS: Casdatifan, after single and multiple dosing in healthy participants, was safe and tolerable. Linear PK was associated with a mean maximum erythropoietin reduction of 85% following a single dose and multiple doses of casdatifan, demonstrating a promising exposure-biological activity profile.